March 2025
Merck Secures $2B Deal with China’s Hengrui for Novel Heart Drug
Merck, Hengrui Pharmaceuticals, HRS-5346, Lipoprotein(a) inhibitor, cardiovascular disease, licensing agreement
Illumina Reshapes Board: Former FDA Chief Takes Chair, Activist Investor Joins
Illumina, Scott Gottlieb, Keith Meister, board changes, genomics, shareholder value
DOGE Reverses Course on FDA Facility Closures, Including Major St. Louis Quality Lab
DOGE, FDA, lease terminations, St. Louis, drug quality lab, cost-cutting, reversal
Trump’s Looming Pharmaceutical Tariffs: Uncertainty and Potential Impact
Trump, pharmaceutical tariffs, trade policy, drug prices, manufacturing, supply chain
Cassava Sciences Discontinues Alzheimer’s Program After Simufilam Fails Second Phase 3 Trial
Cassava Sciences, simufilam, Alzheimer’s disease, Phase 3 trial failure, drug development discontinuation
GSK Launches Groundbreaking Study on Shingrix and Dementia Risk Reduction
GSK, Shingrix, dementia, UK Dementia Research Institute, Health Data Research UK, NHS data, real-world experiment
Surrozen sets its sights on ophthalmology after binning liver programme
Ophthalmology specialty, Severe (severity modifier)
Biogen’s New Global Headquarters: Consolidating Operations in Cambridge
Biogen, Cambridge, Kendall Square, headquarters consolidation, innovation hub, 2028 opening
Future in doubt as Opthea’s AMD drug flunks first pivotal study
Opthea ‘s, Opthea, Future, Clinical Research